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CD73 is a glycosyl-phosphatidylinositol-(GPI-) linked membrane protein that catalyzes the extracellular dephosphorylation of
adenosine monophosphate (AMP) to adenosine. Adenosine is a negative regulator of inflammation and prevents excessive cellular
damage. We investigated the role of extracellular adenosine in the intestinal mucosa during the development of Dextran-Sulfate-
Sodium-(DSS-)salt-induced colitis in mice that lack CD73 (CD73−/−) and are unable to synthesize extracellular adenosine. We
have found that, compared to wild-type (WT) mice, CD73−/− mice are highly susceptible to DSS-induced colitis. CD73−/− mice
exhibit pronounced weight loss, slower weight recovery, an increase in gut permeability, a decrease in expression of tight junctional
adhesion molecules, as well as unresolved inflammation following the removal of DSS. Moreover, colonic epithelia in CD73−/−
mice exhibited increased TLR9 expression, high levels of IL-1β and TNF-α, and constitutive activation of NF-κB. We conclude that
CD73 expression in the colon is critical for regulating the magnitude and the resolution of colonic immune responses.
1. Introduction
Many mechanisms are proposed to lead to chronic inflam-
mation of the gut mucosa, which is exemplified by Crohn’s
disease (CD) and ulcerative colitis (UC), also known as
inflammatory bowel diseases (IBDs) [1]. These include dys-
regulation of the innate immune response to enteric flora
[2, 3], increased epithelial barrier permeability [4], and
defective regulation of the adaptive immune response [5].
Several susceptibility genes carrying mutations have been
found in patients suﬀering from IBD [1]. Mutations in the
human leukocyte antigen genes are associated with both CD
and UC [6], while mutations in the Nuclear Oligomerization
Domain (NOD) 1/2 genes are associated with CD [1, 7].
The passage of soluble molecules across the epithelial
barrier of the gastrointestinal tract is a tightly regulated pro-
cess [8]. Nutrients must be absorbed into the bloodstream,
while commensal bacteria normally found in the GI tract,
and their associated antigens, must be kept isolated from
intraepithelial lymphocytes to avoid abnormal and persistent
immune responses that can cause inflammation or other
types of trauma [8, 9]. The purine nucleoside adenosine, its
receptors and ectoenzymes (CD39 and CD73) are emerging
as critical players in the regulation of intestinal immune-
mediated inflammation [10–12].
During inflammation and the initiation of primary
immune responses, adenosine triphosphate (ATP) is released
into the extracellular environment following cell damage
[13]. Extracellular ATP, a damage-associated molecule and
a potent activator of the immune response, increases the
production of proinflammatory cytokines such as IL-1β, IL-
6, TNF-α, and IL-12. ATP also enhances the potency of the
oxidative stress response of activated macrophages [13]. The
immune system has various mechanisms to resolve these
inflammatory signals. One such mechanism is activated by
the extracellular adenosine generated through the activities
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of CD39 and CD73 [14]. CD39 catabolizes extracellular ATP
to adenosine monophosphate (AMP) while CD73 (a 5′-
ectonucleotidase) further converts AMP to adenosine [15].
Adenosine inhibits production of TNF-α, IL-1β, IL-6, IL-
12, and IL-23 by monocytes and dendritic cells (DCs) and
promotes the production of IL-10 [16]. Therefore, CD73-
generated adenosine acts as a negative feedback signal to
prevent uncontrolled inflammation that would otherwise
cause collateral damage to healthy tissues.
CD39, CD73, and adenosine receptors are expressed on
intestinal epithelial cells and various immune cell types [17–
19]. CD39 and CD73 have recently been shown to be impor-
tant for T regulatory cell function [20], and mice lacking
these enzymes exhibit very severe IBD in trinitrobenzene
sulfonate (TNBS) colitis model [10, 11]. Adenosine medi-
ates its eﬀects through four G protein-coupled receptors:
A1AR; A2AAR; A2BAR; A3AR [14]. Adenosine receptors are
expressed in the intestine of mice and humans, and signaling
through these receptors is critical for regulation of the
severity of intestinal inflammation following a wide range
of insults [16]. For example, activation of the A2A receptor
has been shown to reduce intestinal inflammation in mice by
decreasing leukocyte infiltration and inhibiting proinflam-
matory cytokines [21], while inhibition of adenosine kinase
improves IBD pathology in DSS-induced colitis [22].
Because of the anti-inflammatory role of adenosine and
its association with IBD, we investigated the role of extracel-
lular (CD73-generated) adenosine in DSS-induced colitis in
mice deficient in CD73. CD73−/− mice developed markedly
more severe colitis and exhibit unresolved inflammation and
produce high levels of the proinflammatory cytokines IL-1β
and TNF-α compared to WT mice. Colonic epithelial cells
from CD73−/− mice show increased TLR-9 and NF-κB activ-
ity and have decreased expression of several tight-junction-
associated proteins when compared to WT mice, along
with an associated increase in gastrointestinal permeability.
From these findings, we hypothesize that CD73-generated
adenosine is a key modulator in gut inflammation and IBD
andmediates its eﬀects through regulating inflammation and
maintaining epithelial barrier integrity.
2. Materials and Methods
2.1. Mice. C57BL/6 WT and rag−/− mice were purchased
from Jackson Laboratories. CD73−/− mice were obtained
from Dr. Linda Thompson at the Oklahoma Medical
Research Foundation [23]. Mice were bred and housed under
specific pathogen-free conditions in the mouse facility at
Cornell University. All procedures performed on mice were
approved by the Cornell University IACUC. All mice used in
these experiments were between 8 and 10 weeks old.
2.2. DSS-Induced Experimental Colitis. 3% Dextran Sodium
Sulfate (DSS, MW = 36,000–50,000) was administered in
drinking water to experimental animals [24]. Age-matched
males and females WT and CD73−/− were used in these
experiments. Weight loss was normally observed 4-5 days
after the initiation of DSS treatment, and experiments were
halted after animals lost ∼20% of initial body weight.
2.3. Passively Induced IBD. CD4+ cells were isolated from
processed spleens and lymph nodes of naı¨ve WT and
CD73−/− mice by negative selection using magnetic beads
(Invitrogen). CD4+ cells were further subdivided into
CD4+CD45RBhighCD25− and CD4+CD45RBlowCD25+ pop-
ulations using a BD-Biosciences FACS Aria system. Two
million CD4+CD45RBhigh cells from either WT or CD73−/−
mice were injected into rag−/− mice. Some mice additionally
received 2 × 106 CD4+CD45RBlowCD25+ cells isolated from
either WT or CD73−/− mice. Mice were weighed daily for 45
days to track disease progression.
2.4. Isolation of Primary Colonic Epithelial Cells. Whole
colons were isolated, the lumen exposed by a longitudinal
cut, washed with Ca++Mg++ free HBSS + 2% FBS, cut
into 1-2mm2 sections, and washed 2X with Ca++Mg++ free
HBSS + 2% FBS. The tissue was then incubated for 30min
at 37◦ C in Ca++Mg++ free HBSS + 10% FBS + 1mM
EDTA + 1mM DTT + penicillin/streptomycin. The digest
was filtered through a 70 μm mesh and spun at 200×g
for 10min. Primary colonic epithelial cells include resident
intraepithelial lymphocytes (iELs), as no Percoll gradient was
used to separate this population.
2.5. Flow Cytometry. Cells were isolated either from the
spleen, mesenteric lymph nodes, colonic epithelium, or
colonic patches of mice and processed into a single-cell
suspension. These cells were subsequently stained with rat
anti-mouse CD4, CD25 (BD Biosciences), CD73, and Foxp3
or hamster anti-mouse CD11c (eBioscience) at a 1 : 250
dilution in PBS. After incubating for 30min at 4◦C with the
antibody cocktail, the cells were washed and resuspended in
PBS. FoxP3 staining was performed using the eBioscience
FoxP3-APC kit. Sample data were acquired using a FACScal-
ibur with CellQuest software. Data files were analyzed using
FlowJo software.
2.6. Histology. Hematoxylin and eosin (H&E) staining was
performed by the Cornell University College of Veterinary
Medicine Core Histology lab on formalin fixed tissue sam-
ples. Immunohistochemistry and immunofluorescence were
performed on OCT embedding tissue snap-frozen in liquid
nitrogen-chilled methylbutane and sectioned into 5 μm slices
on a cryostat. Primary antibodies used were CD4, CD45,
CD11c (hamster anti-mouse 1 : 30), and CD321 (JAM-A, rat
anti mouse, 1 : 100). Secondary antibodies used were biotiny-
lated goat anti-rat IgG and biotinylated goat anti-hamster
IgG (1 : 100). For immunohistochemistry, slides were treated
with streptavidin-HRP followed by AEC and counterstained
with hematoxylin. Immunofluorescence staining for CD321
was performed by treating with a 1 : 200 dilution of strep-
tavidin-AF488 for 90 minutes at 37◦C and then fixed in 1%
formalin for 10 minutes.
2.7. Clinical Score and Histological Analysis. Changes in body
weight were assessed as a percent change in body weight
compared to baseline. A scoring system (from 0–4) was
used to determine the presence of occult or overt blood
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Figure 1: CD73−/− mice develop more severe clinical signs of IBD than WT mice. (a) WT (circles) and CD73−/− (squares) mice were given
3% DSS in drinking water and weighed daily for 10 days. Results are represented as % of initial weight (±SEM, summary of 5 experiments,
n = 26, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005). (b) Mean (±SEM, n = 4, ∗P < 0.05, representative of 5 experiments) colonic blood score is
displayed (0 = no blood in colon; 1 = blood in 25% of colon; 2 = blood in 50% of colon; 3 = blood in 75% of colon; 4 = blood in 100% of
colon). (c) Mean (±SEM, n = 4, ∗P < 0.05, representative of 5 experiments) colon length (cm) is displayed, along with (d) a representative
photograph.
in the stool. Colonic inflammatory score was determined
by the extent of inflammatory cell infiltrates (0–3) and
tissue damage (0–3). Scoring was performed in a blinded
manner. Cell infiltration and tissue damage were added and
the combined “colitis severity score” ranged from 0 to 6
(description in legends to Figures 2, 3 and 4).
In Figure 2, (a) histology of colons from WT (top
panels) and CD73−/− (bottom panels) mice treated with 3%
DSS in drinking water. Left two panels show hematoxylin
and eosin (H&E) stains displaying colonic epithelial crypt
histopathology and appearance of granulomas (in CD73−/−)
mice. Right three panels show CD4+ cell (brown) infiltration
in the colon. (b) Mean (±SEM, ∗∗∗∗P < 0.001, n = 8)
colonic inflammatory score is displayed. The scoring scale is
comprised of two components: (i) inflammatory cell infil-
trate (focus of inflammatory cells in the lamina propria = 1,
confluence of inflammatory cells = 2, and transmural exten-
sion of the infiltrates = 3); (ii) tissue damage (discrete lym-
phoepithelial lesions = 1, mucosal erosion = 2 and extensive
mucosal damage and extension through deeper structures
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Figure 2: CD73−/− mice display a higher degree of infiltration in the colon compared to WT mice.
of the bowel wall = 3). The two scores (cell infiltration and
cell damage) are added, and the combined histological colitis
severity score ranges from 0 to 6. (c) Colonic patches from
WT and CD73−/− mice treated with 3% DSS in drinking
water were isolated and stained for CD11c and analyzed
by FACS. Results are displayed as % of CD11c+ cells (data
representative of 3 experiments). (d) Immunohistochemistry
of colons from WT (left) and CD73−/− (right) mice treated
with 3% DSS in drinking water. Sections show CD11c
infiltration in the colons of mice. (e) IL-1β and TNF-α
produced by lymphocytes from colonic patches of CD73−/−
and WT mice after 24-hour incubation in medium without
stimulation. Samples were analyzed by Bio-Plex instrument
(from three diﬀerent experiments, n = 15 mice, ∗P < 0.05,
∗∗P < 0.01, ∗∗∗P < 0.005, ND = not detected).
In Figure 3, (a) CD4+CD45RBhigh T cells from WT
(circles) and CD73−/− (squares) were transferred into
rag−/− mice, which were monitored for 45 days. Results
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Figure 3: CD4+ T cells from CD73−/− mice transfer a similar degree of colitis compared to WT mice and show no defect in Treg suppression
of IBD.
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Figure 4: CD73−/− mice exhibit ongoing inflammation and slower recovery from IBD compared to WT mice. (a) WT (circles) and CD73−/−
(squares) mice were given 3% DSS in drinking water and weighed daily for 35 days. DSS was removed at day 8 and replaced with drinking
water. Results are represented as % of initial weight (±SEM, ∗P < 0.05, one of two representative experiments). (b) H&E staining of colons
from CD73−/− (top) and WT (bottom) mice taken on day 35 (left) compared to naı¨ve (right) mice. (c) Mean (±SEM, ∗P < 0.05, ∗∗P < 0.01)
colonic inflammatory score is displayed (n = 5 mice). The scoring scale is comprised of two components: (i) inflammatory cell infiltrate
(focus of inflammatory cells in the lamina propria = 1, confluence of inflammatory cells = 2, and transmural extension of the infiltrates =
3); (ii) tissue damage (discrete lymphoepithelial lesions = 1, mucosal erosion = 2, and extensive mucosal damage and extension through
deeper structures of the bowel wall = 3). (d) FACS analysis of CD73 expression on colonic epithelial cells from naı¨ve WT (top left panel,
28%) and CD73−/− (bottom left panel, 0%) mice. Colonic epithelial cells identified with CD326/EpCam. Colonic IEL’s identified with CD45
(middle panels, WT 87% CD73+). Mesenteric lymph nodes shown as a positive control (right panels, WT 39% CD73+). (e) IL-1β and TNFα
production in colon preparation isolated from WT and CD73−/− mice on day three of DSS treatment and (f) day eight of DSS treatment. (g)
Colons isolated from WT and CD73−/− mice on day 22 after removal of DSS were cultured (in medium alone) for 24 hours and supernatant
analyzed by Bio-Plex for IL-1β. Results (mean ±SEM, ∗P < 0.05, representative of one experiment, n = 3 mice per group) are presented as
pg/mL IL-1β produced.
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Table 1
Target gene Forward (5′ to 3′) Reverse (5′ to 3′)
JAM-A TCTCTTCACGTCTATGATCCTGG TTTGATGGACTCGTTCTCGGG
Claudin 2 GTACCCTTTTAGGACTTCCTGC CCCACCACAGAGATAATACAAGC
A Catenin TCTCTACTGCCACCAGCTCAAC AAGCCATCCCCTGTGACTTCT
GAPDH CCCCAATGTGTCCGTCGTG GCCTGCTTCACCACCTTCT
TLR1 GTCTCCCCACTTCATCCAGA GCTTGTTCTTCTCTGTGGGC
TLR3 GGTCCCCAGCCTTCAAAGAC ACGAAGAGGGCGGAAAGGT
TLR4 CAGGTGGAATTGTATCGCCT CGAGGCTTTTCCATCCAATA
TLR5 CCACCGAAGACTGCGATGA GTGACCGTGCACAGGATGAA
TLR9 ATG GTT CTC CGT CGA AGG ACT GAG GCT TCA GCT CAC AGG G
PGK1 CTC CGC TTT CAT GTA GAG GAA G GAC ATC TCC TAG TTT GGA CAG TG
(5 mice/group, mean ± SEM, representative of 3 experi-
ments) are displayed as% of initial weight. (b) CD45 staining
of frozen colons from rag−/− mice 45 days after T cell
transfer: (i) WT CD45RB+ donor, (ii) CD73−/− CD45RB+
donor, (iii) WT CD45RB+ and WT CD25+ donors, and
(iv) CD73−/− CD45RB+ and CD73−/− CD25+ donors. (c)
Colonic inflammatory score is displayed with separate scores
for inflammatory cell infiltrate (focus of inflammatory cells
in the lamina propria = 1, confluence of inflammatory
cells = 2 and transmural extension of the infiltrates = 3),
and tissue damage (discrete lymphoepithelial lesions = 1,
mucosal erosion = 2, and extensive mucosal damage and
extension through deeper structures of the bowel wall = 3)
(n = 6 mice, inflammatory cell infiltrate, ±SEM, P = 0.05,
tissue damage, P = 0.4). (D) CD25, CD73, and CD39
expression on CD4+ T cells from mesenteric lymph nodes
and colonic patches of naı¨ve WT and CD73−/− mice. Left-
hand panels show distribution of CD73 on CD4+ cells.
Middle panels show distribution of iELs, and right panels are
gated on CD4+ cells and show distribution of CD25/CD73
and CD25/CD39 expression. (e) CD4+CD45RBhigh and
CD4+CD25+ (CD45RBlo) T cells from WT (circles) or
CD73−/− (squares) were transferred into rag−/− mice.
Results (mean ± SEM, representative of 3 experiments) are
displayed as % of initial weight. (f) FoxP3 expression in
colonic patches and mesenteric lymph nodes from CD73−/−
versus WT mice (representative of two experiments).
2.8. Cytokine Analysis. For Figure 2, colonic patches were
cultured overnight at 37◦C in Bruﬀ ’s media. For Figure 4,
whole colons were isolated from DSS-treated and naı¨ve
CD73−/− and WT animals and cultured overnight at 37◦C
in Bruﬀ ’s media. The culture supernatant was isolated and
frozen at −80◦C. Analysis of cytokine levels was performed
using a Bio-Plex system.
2.9. Real-Time PCR. All data was generated using either the
Thermo Scientific SYBR Green kit and the ABI 7500 Real-
Time PCR machine or the Kapa SYBR FAST qPCR kit and
the Bio-Rad C1000 Real-Time PCR machine. Expression of
all genes was standardized to expression of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) and relativised to WT
expression of the gene in question or was compared to PGK1
(housekeeping gene) expression. Primers, whose sequences
are shown in Table 1, were obtained from IDT.
2.10. Gastrointestinal Permeability. Briefly, mice were fasted
for 3 hrs and were rectally administered 200 μL of 10mg/mL
(0.1mg/g body weight) 10 kDa FITC-dextran (Invitrogen) in
PBS [25]. After 1 hour, mice were bled via their submandibu-
lar vein, the whole blood spun at 2,000×g for 5min, and the
serum isolated. This isolation yielded approximately 150 μL
of serum per animal. Serum fluorescence was measured on
a BioTek (Winooski, VT) Synergy 4 analyzer. FITC-Dextran
concentration was calculated from standard curves generated
by serially diluting FITC-Dextran.
2.11. Western Blotting. Western blot analysis as described in
[26] was performed on colonic epithelial cells of CD73−/−
and WT mice. Briefly, cells (2 × 106) were lysed in reducing
SDS sample buﬀer followed by centrifugation at 18,000 g for
5min. Samples were boiled for 10 minutes after which equal
amounts of total cell lysates were separated by 10% SDS-
PAGE and electrophoresed onto PVDF (Millipore, Bedford,
MA). Samples were incubated with Ab specific for dual-
phosphorylated (active) NF-κB P65 subunit used at the
concentrations recommended by the manufacturer (Cell
Signaling Technology, Beverly, MA) in 5% BSA in Tris
buﬀered saline, 0.1% Tween20 overnight at 4◦C.
3. Results
3.1. CD73−/− Mice Develop More Severe IBD Than WT
Mice. Since CD73 catalyzes the formation of extracellular
immunosuppressive adenosine from damaged cells during
inflammation and is highly expressed on colon tissue [16–
19], we investigated the impact of a lack of CD73 in
the intestinal mucosa. To do this, we induced IBD in
CD73−/− and WT mice by oral treatment with 3% DSS
in drinking water. DSS-induced colitis resulted in signif-
icant weight loss, epithelial damage, and robust colonic
inflammation (Figure 1). Daily monitoring of IBD revealed
that CD73−/−mice developed markedly more severe clinical
signs of IBD, including diarrhea and dehydration (data not
shown), when compared to WT mice (Figure 1). Frequently,
disease had to be aborted before the duration of the 10
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day protocol because greater than 50% of CD73−/− mice
exhibited substantial weight loss and severe rectal bleeding.
This was accompanied by more pronounced weight loss
(Figure 1(a)), higher colonic blood scores (Figure 1(b)), and
shorter colon length (Figure 1(c)).
Histological analyses of the colons of DSS-treated
CD73−/− mice revealed extensive destruction of colonic
epithelial architecture, including epithelial crypt destruction,
massive immune cell infiltration into the lamina propria,
and the appearance of granulomas (in 30% of mice), and
an overall increase in colon inflammatory score compared
to WT mice (Figures 2(a) and 2(b)). These immune cell
infiltrates consist of CD45+ cells (a general marker for
leukocytes, data not shown) with a substantial number
being CD4+ T cells (Figure 2(a)). FACS analysis of colonic
patches (lymphoid aggregates from colon) also revealed a
higher percentage of CD11c+ dendritic cells in CD73−/− mice
compared to WT mice (Figures 2(c) and 2(d)).
We next determined the cytokine profile of infiltrating
leukocytes isolated from the colon of DSS-treated CD73−/−
and WT mice. Cells from colonic patches of CD73−/− mice
produced higher levels of IL-1β compared to those from WT
mice (data not shown). There was no significant diﬀerence
in TNF-α, IFN-γ, IL-17, IL-4, or IL-10 levels between WT
and CD73−/− mice (data not shown). The increase in IL-1β
suggests that infiltrating inflammatory cells into the colon are
capable of contributing to the severe IBD in CD73−/− mice.
3.2. CD45RBhighCD4+ Cells from CD73−/− Mice Transfer Sim-
ilar Degree of Colitis as WT Mice. Due to the immunoregula-
tory eﬀects of localized CD73-driven adenosine production,
we next determined if the severe IBD phenotype observed in
DSS-treated CD73−/− mice was due to a more proinflamma-
tory nature of the CD4+ T-cell population. To address this
question, we induced IBD by transferring CD4+CD45RBhigh
T cells into rag−/− recipients [27]. IBD induced by this
method involves diﬀerential activation of TH-1 cells and can
be inhibited by cotransfer of CD4+CD45RBlow (consisting
of CD25+ T regulatory cells) cells into rag−/− recipients
[28]. CD4+CD45RBhigh cells were isolated from spleens of
naı¨ve WT or CD73−/− mice and adoptively transferred into
rag−/− recipients. Recipients of CD73−/− CD4+CD45RBhigh
T cells exhibited a similar weight loss pattern to those
recipients of WT CD4+CD45RBhigh T cells (Figure 3(a)).
Histological analysis of colons revealed rag−/− mice that
received CD4+CD45RBhigh cells from CD73−/− mice had
significantlymore immune cell infiltration in the lamina pro-
pria compared to recipients of CD4+CD45RBhigh cells from
WT mice (Figures 3(b) and 3(c)). However, the resultant
colonic epithelial damage compared between recipients of
WT and CD73−/− CD4+CD45RBhigh donor cells is not statis-
tically significant (Figures 3(c) and see S1 in supplementary
material available online at doi:101155/2012/260983). This
suggests that the inflammatory immune cells infiltrating the
large intestine is not the sole cause of the very severe IBD
observed in CD73−/− mice.
Recent studies have indicated that CD73 and CD39 are
important for immune suppression by T regulatory cells
[20]. We therefore asked whether CD4+ T regulatory (Treg)
cells from CD73−/− mice were defective in their ability to
suppress IBD. In naı¨veWTmice, fifty percent of CD4+ T cells
express CD73 (Figure 3(d)) and all CD4+CD25+ cells express
both CD73 and CD39 (Figure 3(d)). CD4+CD45RBhigh and
CD4+CD25+ (CD45RBlo) cells from spleens of naı¨ve WT
mice were cotransferred into rag−/− recipients. Similarly,
naı¨ve CD4+CD45RBhigh and CD4+CD25+ (CD45RBlo) cells
from CD73−/− mice were cotransferred into rag−/− recipi-
ents. Rag−/− mice that received CD73−/− CD4+CD45RBhigh
and CD4+CD25+ cells developed no clinical signs of IBD
and showed a similar weight-gain pattern to rag−/− mice
receiving WT CD4+CD45RBhigh and CD4+CD45RBloCD25+
cells (that also showed no signs of IBD) (Figure 3(e)).
Further, similar to WT mice, CD73−/− mice harbor similar
frequency of CD4+ FoxP3+ T cells in colonic patches (lym-
phoid follicles) and mesenteric lymph nodes compared to
those of WT mice (Figure 3(f)) (also in peripheral lymphoid
organs [29]). These results indicate that neither the numbers
nor the function of CD4+Treg cells from CD73−/− mice is
significantly altered and thus is not the only contributing
factor in the severe IBD in CD73−/− mice. From these studies
we conclude that a lack of CD73 expression on CD4+Treg cells
did not majorly hamper their ability to suppress IBD.
3.3. CD73−/− Mice Exhibit Ongoing Inflammation and Slower
Recovery Than WT Mice. Under normal conditions, WT
mice can recover from colitis once DSS treatment is removed
[24]. To determine whether CD73−/− mice can recover from
DSS-induced colitis we replaced DSS with drinking water on
day eight in both WT and CD73−/− mice and monitored
their body weight as an indication of disease alteration.
CD73−/− mice recovered at a slow rate following the removal
of DSS from their drinking water, regaining their initial body
weight 22 days after DSS removal (Figure 4(a)). This was
in sharp contrast to WT mice that regained their initial
body weight seven days after the removal of DSS and gained
an additional 20% of their initial body weight by 22 days
after T DSS removal (Figure 4(a)). Examination of colon
pathology of WT mice after day 22 showed full recovery:
colonic architecture showed little to no cell infiltration, no
tissue damage, and normal looking epithelial crypts and
goblet cells (Figures 4(b) and 4(c)). While CD73−/− mice
(day 22) exhibited significantly reduced colonic pathology
compared to that observed during DSS treatment, they still
show modest cell infiltration, some epithelial hyperplasia,
and noticeable crypt destruction (Figures 4(b) and 4(c)),
indicating prolonged or ongoing inflammation illustrated by
the colonic inflammatory score (Figure 4(c)).
3.4. Increased IL-1β and TNF-α Production in Colonic Epithe-
lium of CD73−/− Compared to WT Mice. While inflamma-
tory immune cells lacking CD73 play an important role
in IBD pathogenesis in CD73−/− mice (Figure 3(b)), it is
apparent that they are not the only contributing factor that
result in the very severe IBD. We next focused our attention
on the colonic epithelium that is comprised of a single layer
of intestinal epithelial cells that forms a physical as well as
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a chemical barrier between the host and the microbial com-
munity [30]. FACS analysis of colonic epithelial cells from
naı¨veWTmice, double stained with an epithelial marker plus
CD73, showed that about 40% of epithelial cells expressed
CD73 (including intraepithelial lymphocytes (iELs) which
make up about 10% of CD73+ cells) (Figure 4(d)).
We next focused on the colon in CD73−/− mice. We
reasoned that the lack of CD73 expression on the colonic
epithelium must contribute significantly to the severe IBD,
since the immune cells lacking CD73 cannot recapitulate the
severe colitis in CD73−/− mice. The intestinal epithelium
closely interacts with underlying mucosal immune cells to
control the immune response [2, 31]. The intestinal epithe-
lium and its products determine whether the underlying
immune status is suppressive or inflammatory. Damage or
activation of the epithelial barrier results in production of
inflammatory mediators by immune cells and epithelial cells
[8]. We hypothesized that the lack of CD73 expression on
colonic epithelial cells might contribute to the heightened
proinflammatory conditions in IBD in CD73−/− mice.
We isolated colons of WT and CD73−/− mice over the
course of DSS treatment, including the period after DSS
removal, cultured them in media overnight, and analyzed
supernatants for cytokines by ELISA. We focused specifically
on IL-1β and TNF-α, as these cytokines are implicated in
colitis both in mice and humans [32]. Further, extracellular
adenosine is a potent regulator of proinflammatory cytokines
including IL-1β and TNF-α [14]. Colons from CD73−/−
mice produced dramatically higher levels of IL-1β (more
than 10-fold) and with slight increase in TNF-α on day 3
of DSS treatment compared to WT (Figure 4(e)). By day
8 of DSS treatment, CD73−/− mice consistently produced
significantly higher levels of these cytokines compared to
WT mice (Figure 4(f)). Furthermore, supernatants from
colons isolated after DSS removal (day 22) show significantly
higher levels of IL-1β (similar to day 8 of DSS, but not
TNF-α) observed in CD73−/− mice (Figure 4(g)). IL-1β and
TNF-α are potent proinflammatory factors that stimulate
proliferation, apoptosis, phagocytosis, and transmigration
of cells across epithelial and endothelial barriers as well as
activate innate receptors on innate immune and epithelial
cells [33]. The increased production of IL-1β and TNF-α is
tightly correlated with IBD severity and tissue destruction
in animals and human patients [1] and is consistent with
the severe colitis and apparent lack of resolution of the
inflammatory process in CD73−/− mice.
3.5. Increased Activation of NF-κB in CD73−/− Mice Com-
pared to WT Mice. IL-1β induces the phosphorylation of IκB
resulting in its degradation and the activation of NF-κB
[34]. The constitutive activation of NF-κB is associated with
aberrant expression of proinflammatory genes induced by
cytokines such as IL-1β and is linked to the pathogenesis of
IBD in both human andmice [35]. Adenosine is a potent reg-
ulator of IL-1β, and IL-1β can increase the expression of the
A2A adenosine receptor [36]. Further, adenosine is a negative
regulator of NF-κB activation in human intestinal epithelial
cells [36]. Thus, we hypothesize that constitutive production
of IL-1β in CD73−/− mouse colonic epithelia (including
intraepithelial lymphocytes) even after DSS removal may
cause constitutive activation of NF-κB. To investigate this, we
isolated colonic epithelial cells from WT and CD73−/− mice
over the course of IBD and tested them for presence of NF-
κB activity. Figure S2 shows that, at various disease intervals,
NF-κB p65 protein is augmented in colonic epithelial cells in
CD73−/− compared to WT mice. These findings suggest that
the lack of extracellular adenosine may result in prolonged
NF-κB activity after the inflammatory trigger (DSS) is
removed. This inflammatory program, through constitutive
production of IL-1β, can promote a proinflammatory feed-
back loop and a vicious inflammatory cycle.
3.6. Increased Intestinal Inflammation Is Associated with
Increased Intestinal Permeability and Decreased Expression of
Tight-Junction Associated Proteins in the Colons of CD73−/−
Mice. In IBD patients and animal models of IBD, increased
inflammation strongly correlates with an increase in intesti-
nal permeability and vice versa [37, 38]. To determine if
intestinal barrier permeability is altered, we examined the
barrier integrity in CD73−/− and WT mice by treating mice
rectally with FITC-Dextran and measuring its concentration
in sera one hour later. As shown in Figure 5(a), CD73−/−
mice exhibit significant increase in gastrointestinal perme-
ability compared to WT. The protective barrier function
of the intestinal epithelium is regulated by intercellular
tight junctions that seal the space between epithelial cells
[31]. Tight junction molecules are comprised of occludins,
claudins, and JAM proteins [31]. Further, JAM-A/JAM-1 has
been shown to be critical in the maintenance of epithelial
barrier permeability, as JAM-A−/− mice have increased
leukocyte infiltration and increased mucosal barrier per-
meability to macromolecules in the intestinal mucosa [39].
We analyzed mRNA transcript levels of several junction
molecules that are associated with tight-junction stability to
determine if the loss of these factors could be responsible for
the destruction of the colonic architecture observed in DSS-
treated CD73−/− mice. We observed a significant decrease in
the mRNA levels of JAM-A, α-Catenin, and Claudin 2
in the colons of CD73−/− mice compared to WT mice
(Figure 5(b)). Furthermore, immunofluorescence staining
with anti-JAM-A antibody shows JAM-A protein expression
is decreased at the borders of epithelial cells in naı¨ve CD73−/−
mice, while expression is localized to the plasma membrane
in naı¨ve WT mice (Figure 5(c)). These findings further
demonstrate that extracellular adenosine is important in
regulation and maintenance of intestinal barrier integrity.
3.7. TLR9 Is Upregulated in Colons of CD73−/− Mice during
IBD. To further evaluate the status of the colonic epithelia
and their ensuing inflammatory state, we next focused
on Toll-like receptors (TLRs) [40]. We hypothesize that
the ongoing inflammation in CD73−/− mice is due to a
breakdown of the intestinal epithelial barrier that leads
to leakage of luminal antigens into the lamina propria
and activation of innate receptors. Intestinal epithelial cells
express a spectrum of Toll-like receptors (TLRs), recognize
and respond to microbial products (MAMP/PAMPS), and
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Figure 5: Upregulation of TLR9 in CD73−/− decreased expression of tight-junction associated proteins observed in the colons of CD73−/−
mice compared to WT mice. (a) Colonic permeability was determined in WT and CD73−/− mice. Serum concentrations of FITC-Dextran
(MW 10,000) in WT (gray bar) and CD73−/− (black bar) mice were obtained following rectal administration of 10KDa FITC-Dextran
(0.5mg/Kg) and measuring FITC-Dextran in the blood 1 hour later. Results are expressed as mean ±SEM, n = 5, ∗P < 0.05). Results are
expressed as (mean ±SEM, n > 3, ∗P < 0.05) relative fluorescence compared to WT. (b) Colons of WT (gray bars) and CD73−/− (black bars)
were analyzed for mRNA expression of the adhesion molecules JAM-A, αCatenin, and Claudin-2. Results are expressed as (mean ±SEM,
n = 3, ∗P < 0.05, ∗∗P < 0.01) fold increase in CD73−/− compared to WT. (c) Fluorescent microscopy of colons from naı¨ve WT (left panel)
and CD73−/− (right panel) mice stained for JAM-A (green). (d) Colons were isolated from CD73−/− or WT mice over the course of IBD
and analyzed for TLR9 mRNA expression by real-time PCR. Results are presented as TLR9 expression level relative to the housekeeping gene
PGK1. (Representative of 3 experiments.)
can trigger inflammatory responses bymucosal immune cells
[41]. To determine if the lack of CD73 expression on the
colon results in increased expression of TLRs, we analyzed
colons of IBD WT and CD73−/− mice by quantitative
PCR analysis for mRNA expression. WT mice expressed
background mRNA levels of a few TLRs, while other TLRs
are not detected (Figure S3). In stark contrast, CD73−/−
mice express more than 10-fold higher levels of TLR9 and
just above background levels of TLR 3 and 5 (Figure S3).
To determine the onset of TLR9 expression over the course
of DSS treatment, we analyzed colons at diﬀerent time
points during IBD. We observed consistent increase in TLR9
expression in the latter stages of IBD (Figure 5(d)). These
findings strongly support the idea of a more activated and
proinflammatory state of the colonic epithelium in CD73−/−
mice compared to WT mice.
4. Discussion
The goal of this study was to determine the role of extracel-
lular adenosine in the regulation of intestinal inflammation.
We demonstrate that mice lacking CD73 (and thus unable to
adequately synthesize extracellular adenosine) exhibit severe
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colitis induced by DSS treatment. This finding is consistent
with previous studies that showed CD73−/− mice presented
a more severe IBD induced by trinitrobenzene sulfonate
(TNBS) administration than their WT counterparts [11]. In
this study, CD73−/− mice were found deficient in INF-α,
which may be important for regulating colonic inflamma-
tion. Here, we demonstrate that CD73−/− mice are unable
to resolve inflammation even after the removal of DSS.
Compared to WT mice, colonic epithelia from CD73−/−
mice produced consistently high levels of IL-1β and TNF-
α that correlate with increased NF-κB and TLR9 expression
and resultant gastrointestinal permeability. In this study,
we demonstrate that heightened inflammation, induced by
aggressive inflammatory immune cells, activated inflamma-
tory colonic epithelial cells and increased intestinal barrier
permeability result in severe unresolved DSS-induced colitis
in mice lacking CD73. Similar outcomes from previous
studies demonstrate that CD73−/− mice presented more
severe IBD, while these two studies use diﬀerent approaches.
CD73−/− mice exhibit massive immune cell infiltration
into the colon. The infiltrating cells are comprised pri-
marily of CD4+ T cells and dendritic cells. These CD4+ T
cells in CD73−/− mice produced high levels of the proin-
flammatory cytokines IL-1β and TNF-α, which are known
to play a major role in the pathogenesis of IBD in
humans and mice. However, adoptive transfer of naı¨ve
CD4+CD45RBhigh (inducer) T cells from CD73−/− mice into
naive rag−/−cd73+/+ recipients shows that while these mice
developed severe colitis, the extent of the tissue damage was
not dramatically diﬀerent when compared to recipients that
received CD4+CD45RBhigh T cells from WT mice. These
findings suggest that the infiltrating immune cells are not the
only cause of the severe IBD in CD73−/− mice. Furthermore,
cotransfer of regulatory T cells from either WT or CD73−/−
mice prevented weight loss and intestinal pathology to an
equal degree. Thus, CD4+Treg cells lacking CD73 are not
defective in their ability to suppress IBD and therefore are
not a major contributor to the severe IBD in CD73−/− mice.
From these observations, we determined that, while the lack
of CD73 expression on immune cells contributed to the
pathogenesis of IBD, this was not the major cause of the
extensive pathology and ongoing inflammation observed in
CD73−/− mice with colitis. We propose therefore that lack
of CD73 expression on the colonic epithelium itself plays a
critical role in IBD in CD73−/− mice.
CD73−/− mice also exhibited a higher frequency of
CD11c+ DCs infiltration in the colon. Mucosal DCs located
in the epithelial dome of the colonic patches or in colonic
lymphoid follicles are known to be involved in endocytosis
and presentation of luminal antigens [42, 43]. The colonic
epithelium is critical for maintenance of immune home-
ostasis in the colonic environment [44–46]. It does this in
part by keeping mucosal DCs in a quiescent state [44–46].
The location and increase in these DCs suggest that they
may be involved in presentation of luminal antigens and
propagation of colonic inflammatory immune responses,
driven by the activated inflammatory colonic epithelial cells
in CD73−/− mice. It is also possible that CD73 expression
on the intestinal vasculature could play a role in regulating
intestinal inflammation. Future studies would be able to
address these questions.
The intestinal epithelium plays a critical role in main-
taining the homeostasis of the intestinal environment [8].
It does this in multiple ways including regulation of TLRs,
NF-κB, innate and adaptive immune responses, as well as by
providing a physical barrier comprised of junction molecules
that separate the luminal contents from the underlying lam-
ina propria [8]. Whole colons from DSS-treated CD73−/−
mice produce high levels of TNF-α and IL-1β over the course
of DSS treatment. IL-1β was detectable in colonic epithelial
preparation in non-DSS-treated CD73−/− mice and remains
elevated even after DSS treatment is aborted. Both IL-1β
and TNF-α are well-known contributors to the pathogenesis
of colitis in mice and humans [32]. Consistent with this
ongoing inflammatory program, constitutively high levels of
the transcription factor NF-κB, which is a critical mediator in
inflammatory and remodeling responses, are also observed.
Both IL-1β and TNF-α are potent activators of NF-κB. NF-
κB is a key player in the cycle of inflammation in CD
and is found constitutively active in colonic epithelial cells
in IBD [47]. Adenosine is a negative regulator of NF-κB
in human intestinal epithelial cells [36, 47]. The increase
in IL-1β levels during and after DSS treatment correlates
with active NF-κB protein and ongoing inflammation and
pathology in colons of CD73−/− mice. Although IL-1β is
observed in non-DSS-treated CD73−/− mice, albeit lower
than is seen in DSS treatment, these mice do not display any
signs of colon pathology. Therefore, we hypothesize that an
inflammatory trigger (DSS) in the absence of extracellular
adenosine in CD73−/− mice results in elevated IL-1β that is
unresolved even after the trigger is removed. This potentially
can contribute to the severe and unresolved inflammation in
CD73−/− but not in WT mice.
Intestinal epithelial cells express a spectrum of Toll-
like receptors (TLRs), recognize and respond to microbial
products (MAMP/PAMPS), and can trigger inflammatory
responses by mucosal immune cells. Studies have shown that
exposure of the apical side of a polarized epithelial barrier to
the TLR9 ligand, CpG DNA, results in a decreased ability to
produce inflammatory cytokines, such as IL-6 and IL-8 [41,
48]. However, basolateral stimulation of the epithelial barrier
with the same agent resulted in a potent proinflammatory
response [48]. Colons of CD73−/− mice with colitis exhibited
increased TLR9 expression that is consistent with the height-
ened and unresolved inflammation in CD73−/− mice but not
inWTmice with colitis. Increased TLR9 expression, together
with the increase in proinflammatory cytokines such as TNF-
α and constitutive NF-κB activity, is indicative of an activated
intestinal epithelium. We hypothesize that the ongoing
inflammation in CD73−/− mice could potentially be due to
a breakdown of the intestinal epithelial barrier that leads
to leakage of luminal antigens (PAMPS/MAMPS) into the
lamina propria and activation of innate receptors like TLR9.
Altered TLR expression is commonly associated with chronic
inflammatory diseases including IBD. An inflammatory
reaction is only required when an antigen is able to bypass
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the protective epithelial barrier. Consistent with the idea
of a severely compromised barrier, CD73−/− mice express
significantly lower levels of JAM-A protein and decreased
levels of JAM-4 and α-catenin transcripts. The increased
gastrointestinal permeability in CD73−/− mice would allow
easy passage of commensal bacteria or their ligands across
the epithelial barrier, resulting in stimulation of basolateral
TLRs and production of proinflammatory cytokines. These
findings strongly indicate that the lack of CD73 expression
on colonic epithelial cells plays a critical role in the ongoing
inflammation in CD73−/− mice. This leads us to conclude
that extracellular adenosine function in the colon is critical
for regulation of colonic immune responses and for the
resolution of the inflammatory program and establishment
of intestinal homeostasis.
In summary, our data show that the lack of CD73 expres-
sion on eﬀector immune cells and on colonic epithelium
causes severe IBD in CD73−/− mice. While eﬀector immune
cells in CD73−/− mice contribute to IBD pathogenesis, it
appears that the greater degree of inflammation and colonic
tissue damage is caused by a lack of CD73 expression
on the colonic epithelium. This results in breakdown of
the epithelial barrier, possibly leading to infiltration of
luminal antigens and subsequent presentation of microbial
products and activation of immune responses by innate and
adaptive immune cells. This perpetuates a vicious cycle of
unresolved inflammation due to the lack of CD73-generated
adenosine. We conclude therefore that CD73 expression on
colonic immune cells is important for immune regulation
whereas CD73 expression on colonic tissue is critical for
regulating the magnitude and the resolution of the mucosal
immune response. These studies provide deeper insights into
adenosine’s role in mucosal immunity and demonstrate the
potential for future development of adenosinergic therapy in
treatment of colitis.
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